Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Herpes simplex virus vectors for gene therapy

D S Latchman1

  • 1Department of Molecular Pathology, University College London Medical School, UK.

Molecular Biotechnology
|October 1, 1994
PubMed
Summary

Herpes simplex virus (HSV) shows promise as a gene therapy vector for the nervous system. New methods simplify gene insertion and improve safety, offering hope for clinical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.

Oncogene·2023
Same author

STAT1 deficiency in the heart protects against myocardial infarction by enhancing autophagy.

Journal of cellular and molecular medicine·2011
Same author

Herpes simplex virus life cycle and the design of viral vectors.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

Growth of herpes simplex virus and purification of viral DNA.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

HSV-Cellular Protein Interactions.

Methods in molecular medicine·2011
Same author

EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A.

Oncogene·2010

Area of Science:

  • Neuroscience
  • Virology
  • Gene Therapy

Background:

  • Herpes simplex virus (HSV) possesses advantageous characteristics for gene delivery to the nervous system, including large capacity, broad host range, and establishment of persistent, asymptomatic neuronal infections.
  • However, HSV's large size and manipulation challenges have limited its vector applications compared to smaller viruses like retroviruses.
  • Concerns regarding HSV's potential for lytic replication and encephalitis in the brain necessitate safety improvements for human use.

Purpose of the Study:

  • To review novel strategies for enhancing HSV as a gene therapy vector.
  • To address challenges related to gene insertion and viral safety.
  • To highlight the potential of improved HSV vectors in future gene therapy.

Main Methods:

  • Review of recent advancements in genetic engineering techniques for HSV.
  • Analysis of safety modifications to mitigate viral neurotoxicity.
  • Discussion of methods for simplified foreign gene insertion into the HSV genome.

Main Results:

  • Development of simplified gene insertion methods for HSV vectors.
  • Implementation of safety enhancements to reduce risks associated with HSV replication in neural tissues.
  • Demonstration of HSV's potential for long-term gene expression in neuronal cells.

Conclusions:

  • Advances in HSV vector technology are overcoming previous limitations in gene therapy.
  • New approaches enhance the safety and ease of use of HSV for delivering genes to the nervous system.
  • Optimized HSV vectors hold significant promise for future clinical gene therapy applications.

Related Experiment Videos